Based on the key indicators obtained from Purple Biotech's historical financial statements, Purple Biotech may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Purple Biotech's Net Invested Capital is comparatively stable compared to the past year. Short Term Debt is likely to gain to about 363.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024. Key indicators impacting Purple Biotech's financial strength include:
The essential information of the day-to-day investment outlook for Purple Biotech includes many different criteria found on its balance sheet. An individual investor should monitor Purple Biotech's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Purple Biotech.
Net Income
(18.89 Million)
Purple
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
Change To Inventory
Change In Cash
Stock Based Compensation
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Property Plant And Equipment Net
Non Current Assets Total
Property Plant And Equipment Gross
Other Liab
Net Tangible Assets
Short Term Investments
Inventory
Property Plant Equipment
Net Invested Capital
Net Working Capital
Short Term Debt
Intangible Assets
Short Long Term Debt Total
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Interest Income
Interest Income
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Minority Interest
Total Revenue
Gross Profit
Reconciled Depreciation
Cost Of Revenue
Selling And Marketing Expenses
Probability Of Bankruptcy
Understanding current and past Purple Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Purple Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Purple Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Purple Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Purple Biotech. Check Purple Biotech's Beneish M Score to see the likelihood of Purple Biotech's management manipulating its earnings.
Purple Biotech Stock Summary
Purple Biotech competes with Pluri, BioLineRx, Enlivex Therapeutics, Anebulo Pharmaceuticals, and Pmv Pharmaceuticals. Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Foreign Associate
Israel
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Purple Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Purple Biotech competition to find correlations between indicators driving Purple Biotech's intrinsic value. More Info.
Purple Biotech is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers . At this time, Purple Biotech's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Purple Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Purple Biotech Systematic Risk
Purple Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Purple Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Purple Biotech correlated with the market. If Beta is less than 0 Purple Biotech generally moves in the opposite direction as compared to the market. If Purple Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Purple Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Purple Biotech is generally in the same direction as the market. If Beta > 1 Purple Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Purple Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Purple Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Purple Biotech growth as a starting point in their analysis.
Purple Biotech November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Purple Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Purple Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Purple Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Purple Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Purple Biotech's daily price indicators and compare them against related drivers.
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.